Open an account

Insight Molecular Diagnostics

IMDX · NASDAQ

$3.03+$0.14 (+4.84%)TodayMarket closed ·
Prev close $2.89

About IMDX

Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 55 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Employees
57
Headquarters
Nashville, Tennessee
Listed
Dec 30, 2015
Sector
Health Care
Industry
Biotechnology
Website
imdxinc.com

IMDX key statistics

Market cap
99.15M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
316.15K
Volume
316.11K
Open price
$2.96
High today
$3.28
Low today
$2.96
52 Week high
$8.51
52 Week low
$2.42

Insight Molecular Diagnostics (IMDX) at a glance

As of Oct 20, 2026, Insight Molecular Diagnostics (IMDX) shares are priced at $3.03, giving the company a market cap of 99.15M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.96 and $3.28. The current price is 2.4% above the day's low and 7.5% below its high.

Volume so far is 316.11K shares, in line with the average of 316.15K shares a day.

Over the past year Insight Molecular Diagnostics has ranged from $2.42 to $8.51, and now sits 10% of the way up that range.

Insight Molecular Diagnostics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.31 per share against an estimate of -$0.2491.

The average analyst price target is $9.86, 225.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $9.86
Low
$8.08
Now
$3.03
High
$12.60

IMDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 55.0% on average.

  1. Q3 FY24: reported -$0.98 per share against an estimate of -$0.4447
  2. Q4 FY24: reported -$1.93 per share against an estimate of -$0.4359
  3. Q1 FY25: reported -$0.26 per share against an estimate of -$0.2412
  4. Q2 FY25: reported -$0.30 per share against an estimate of -$0.2346
  5. Q3 FY25: reported -$0.34 per share against an estimate of -$0.2139
  6. Q4 FY25: reported -$0.72 per share against an estimate of -$0.242
  7. Q1 FY26: reported -$0.12 per share against an estimate of -$0.2667
  8. Q2 FY26: reported -$0.31 per share against an estimate of -$0.2491

IMDX news

  • Press releaseGlobe Newswire

    IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

  • Press releaseGlobe Newswire

    IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

  • Press releaseGlobe Newswire

    iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as Insight Molecular Diagnostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.